Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Daunorubicin price, strengths & recalls

Daunorubicin has no weekly pharmacy acquisition cost. 2 manufacturers make it. It has 2 recalls on record, none ongoing. Its official label last changed on February 9, 2023.

Generic
No weekly pricePharmacy acquisition costs aren't published for this drug - usually because it's given in clinics or hospitals.

Daunorubicin price by strength

What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
5 mg/mL, 4 mL injectionNot priced this week

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recalls2 recalls on record, latest Aug 25, 2021

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for daunorubicin? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedFebruary 9, 2023
Version4
EffectiveJan 1, 2023
Read the label

DAUNORUBICIN HYDROCHLORIDE INJECTION Rx ONLY

This drug has a boxed warning

WARNING

Daunorubicin Hydrochloride Injection must be given into a rapidly flowing intravenous infusion. It must never be given by the intramuscular or subcutaneous route. Severe local tissue necrosis will occur if there is extravasation during administration.

Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m

2 in adults, 300 mg/m

2 in children more than 2 years of age, or 10 mg/kg in children less than 2 years of age.

Severe myelosuppression occurs when used in therapeutic doses; this may lead to infection or hemorrhage.

It is recommended that daunorubicin hydrochloride be administered only by physicians who are experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.

Dosage should be reduced in patients with impaired hepatic or renal function.

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Generic makers
2 approved generic applications on the market

Daunorubicin questions

Is daunorubicin in shortage?

No shortage is reported for daunorubicin right now. We check the national shortage list every day.

Has daunorubicin been recalled?

2 recalls on record, none ongoing. Recalls name specific lots - check yours.

When did the daunorubicin label last change?

The official label was last updated on February 9, 2023 (version 4). See what changed.

Talk about daunorubicin

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.